V médiích

• FNKV.cz – MUDr. Ondřej Gojiš, Ph.D. obdržel prestižní vědecké ocenění
• Právě Dnes – Ondřej Gojiš
• Klub Doktora Vlacha – Letošní cenu Česká hlava získal i jeden lékař
• J. Hejrovský Institute of Physical Chemistry – Česká Hlava Informuje
• Tretiruka.cz – Kdo jsou letošní České hlavy?
• CZECH INVEST – Šest Českých hlav se dočkalo ocenění
• Česká Televize – Studio 6 – Ondřej Gojiš
• Česká hlava 2014 – Slavnostní předávání cen za největší vědecké počiny a výzkumy (9:45 – 15:46)
• Psychosomatika a prevence v gynekologii – rozhovor s MUDr. Ondřejem Gojišem, Ph.D.

Publikační činnost

• SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.
• Zwart W, Flach KD, Rudraraju B, Abdel-Fatah TM, Gojis O, Canisius S, Moore D, Nevedomskaya E, Opdam M, Droog M, Hofland I, Chan S, Shaw J, Ellis IO, Coombes RC, Carroll JS, Ali S, Palmieri C.
  Clin Cancer Res. 2015 Sep 14. [Epub ahead of print]
• ‍Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
• Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D,Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ.
  Oncotarget. 2015 Aug 21. [Epub ahead of print]
• Expression of selected proteins in breast cancer brain metastases.
• Gojis O, Kubecova M, Rosina J, Vranova J, Celko M, Frajerova D, Zmrhal J, Zahumensky J, Bacova T, Baca V, Mandys V, Kucera E.
  Folia Histochem Cytobiol. 2013;51(3):213-8. doi: 10.5603/FHC.2013.0030.
• The injury of bladder without penetrate during the TVT surgery for stress incontinence.
• Popelka J, Zmrhal J, Gojiš O.
  Ceska Gynekol. 2013 Aug;78(4):356-9. Czech.
• Cooperation between mammologist and radiodiagnostic in the management of mammary leasions in the University Hospital Kralovské Vinohrady.
• Bendová M, Malina R, Gojiš O, Večeřová L, Zemanová G.
  Ceska Gynekol. 2013 Aug;78(4):333-7. Review. Czech.
• Velamentous insertion of the umbilical cord of twin B as a cause of vasa previa in monochorionic diamniotic twins.
• Zahumensky J, Gojis O, Kiss I, Kucera E.
  Int J Gynaecol Obstet. 2013 Sep;122(3):261-2. doi: 10.1016/j.ijgo.2013.04.011. Epub 2013 Jun 21. No abstract available.
• Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance.
• Palmieri C, Gojis O, Rudraraju B, Stamp-Vincent C, Wilson D, Langdon S, Gourley C, Faratian D.
  Br J Cancer. 2013 May 28;108(10):2039-44. doi: 10.1038/bjc.2013.199. Epub 2013 May 7.
• Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.
• Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.
  Br J Cancer. 2012 Aug 7;107(4):732-8. doi: 10.1038/bjc.2012.308. Epub 2012 Jul 10.
• Reproductive functions in women after cancer therapy.
• Záhumenský J, Feldmár P, Kučera E, Zmrhal J, Gojiš O, Kosová T, Bendová M, Stejskal D.
  Klin Onkol. 2012;25(3):173-7. Review. Czech.
• NT5E CpG island methylation is a favourable breast cancer biomarker.
• Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, SyedN, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.
  Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.
• Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.
• Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.
  Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.
• Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
• Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS.
  Nature. 2012 Jan 4;481(7381):389-93. doi: 10.1038/nature10730.
• High frequency of complex TP53 mutations in CNS metastases from breast cancer.
• Lo Nigro C, Vivenza D, Monteverde M, Lattanzio L, Gojis O, Garrone O, Comino A, Merlano M, Quinlan PR, Syed N, Purdie CA, Thompson A, Palmieri C, Crook T.
  Br J Cancer. 2012 Jan 17;106(2):397-404. doi: 10.1038/bjc.2011.464. Epub 2011 Dec 20.
• Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome.
• Krell J, James CR, Shah D, Gojis O, Lim A, Riddle P, Ahmad R, Makris A, Cowdray A, Chow A, Babayev T, Madden P, Leonard R, Cleator S, Palmieri C.
  Clin Breast Cancer. 2011 Jun;11(3):153-60. doi: 10.1016/j.clbc.2011.03.012. Epub 2011 Apr 20.
• Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
• Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S.
  Clin Breast Cancer. 2011 Apr;11(2):93-102. doi: 10.1016/j.clbc.2011.03.001. Epub 2011 Apr 11.
• The role of SRC-3 in human breast cancer.
• Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, Coombes RC, Cleator S, Palmieri C.
  Nat Rev Clin Oncol. 2010 Feb;7(2):83-9. doi: 10.1038/nrclinonc.2009.219. Epub 2009 Dec 22. Review. Erratum in: Nat Rev Clin Oncol. 2010 Mar;7(3):122. Coombes, Charles R [corrected to Coombes, R Charles].
• Poor reception?
• Alifrangis C, Harcourt JP, Gojis O, Palmieri C.
  Lancet. 2009 Sep 12;374(9693):948. doi: 10.1016/S0140-6736(09)61120-X. No abstract available.
• An unusual triple-negative breast carcinoma.
• Shousha S, Peston D, Gojis O, Palmieri C.
  Histopathology. 2009 Sep;55(3):364-6. doi: 10.1111/j.1365-2559.2009.03349.x. No abstract available.
• The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease.
• Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P, Palmieri C.
  Eur J Surg Oncol. 2010 Mar;36(3):224-9. doi: 10.1016/j.ejso.2009.08.002. Epub 2009 Aug 28. Review.
• FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
• Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, Lam EW.
  Int J Oncol. 2009 Jul;35(1):57-68.
• Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?
• Palmieri C, Gojis O, Rudraraju B, Cleator S.
  J Clin Oncol. 2008 Dec 10;26(35):5824; author reply 5825-6. doi: 10.1200/JCO.2008.19.5529. Epub 2008 Nov 10. No abstract available.
• Guided tissue regeneration, barrier membranes and reconstruction of the cleft maxillary alveolus.
• Duskova M, Leamerova E, Sosna B, Gojis O.
  J Craniofac Surg. 2006 Nov;17(6):1153-60.
• Reconstruction of maxilla alveolus for application of dental implant in patients with cleft defect.
• Dusková M, Koťová M, Urban F, Sosna B, Jirkalová R, Strnadel T, Kristen M, Leamerová E, Gojis O.
  Acta Chir Plast. 2004;46(4):115-21.

Publikační abstrakta

• The Role of Steroid Sulfatase in Regulating Stromal-Epithelial Interactions in the Breast and Prostate.
  Endocrinology and Metabolic Medicine and Sterix Ltd, Imperial College London, St Mary’s Hospital, London W2 1NY, UK; Cancer Research UK Laboratories, Imperial College London, Hammersmith A. Purohit, H. J. Tutill, J. M. Day, O. Gojis, C. Palmieri and M. J. Reed: Hospital, London W12 0NN, UK. The endocrine society annual meeting, 2009, USA.

Postery

• Phan, Shousha, Gojis: CD10- an important marker in the profiling of triple negative breast cancer. 22nd European congress of Pathology – European Society of Pathology,2009, Florence, Italy.
• Shah, Gojis, Krell, Ahmad, Riddle, Coombes, Leonard, Fox, Cleator, Palmieri: Management and outcome of HER2-positive breast cancer treated with and without adjuvant trastuzumab: The Imperial College London experience. J Clin Oncol 28:7s, 2010 (suppl; abstr 650). ASCO 2010
• Marla, Cardale, Dodwell, Skene, Gojis, Palmieri, Abram, Cleator, Bowman, Doughty: HER2-positive early breast cancers: What proportion are receiving adjuvant trastuzumab therapy? A multicenter audit. J Clin Oncol 28:7s, 2010 (suppl; abstr 668) ASCO 2010
• Alifrangis, Shipway, Gojis, Emson, Mackie, Coombes, Palmieri: A phase II cross-over study of docetaxel versus vinorelbine in anthracycline-resistant, advanced breast cancer. J Clin Oncol 28:7s, 2010 (suppl; abstr 1097). ASCO 2010

Kongresy

• 2008  Onkologické symposium – Cambridge 2008: management péče o pacienty s karcinomem prsu -aktivní příspěvek – terapie chronické bolesti (Master class of oncology – Breast cancer management)
• 2010  Kongres evropské onkochirugické společnosti – European Society for Surgical Oncology (ESSO) – Bordeaux 2010: O.Gojis: The role of AIB1 in human breast cancer.
• 2010  Mezinárodní vědecká conference pro PGS student Hradec Králové 2010 – International Postgraduate Conference Hradec Králové 2010: O.Gojis: The role of AIB1 in human breast cancer.
• 2011  konference ČGPS – sekce Infekce v gynekologii a porodnictví – 4 konference, Praha, přednáška: HPV infekce v těhotenství (Gojiš, Záhumenský)
• 2011  Kaňkův onkologický den
• 2012  Celostátní conference ČGPS – Brno
• 2013  Konference Gynekologické urologie, Nové zámky, Slovensko: Co víme o uretře?
• 2013  Konference urogynekologické společnosti – Co víme o uretře?
• 2014  Celostátní conference ČGPS, Brno: posterová sekce: Role nádorových marker v onkogenezi karcinomu prsu
• 2015  Celostátní konference České urogynekologické společnosti: Operační léčba sestupu pánevních orgánů pomocí “single incision” kotvených implantátů – prospektivní analýza dat.

Objednejte se k lékaři